Merlin Crossley, AM[1] is an Australian molecular biologist, university teacher, and administrator. He is Deputy Vice-Chancellor (DVC) Academic Quality at the University of New South Wales.[2]
Crossley has held senior roles at both the University of Sydney and the University of New South Wales. He has led the research portfolio, and the teaching portfolio. He is most well known for overseeing the introduction, in 2017, of Education Focussed Careers at University of New South Wales. The idea was to formally recognise that the university relied on academics who were primarily dedicated to teaching and to supporting students. Previously the university had sought to ensure that all academics were 'research active', but now appreciates that a good team requires batters, bowlers, and all-rounders. Academics can be promoted for their work in any area. Many argue that, as well as boosting morale, this change has improved the student experience and even contributed to an uplift in the overall quality of research, as only those committed to research generate outputs.
Research
Crossley is interested in gene regulation. He studied an unusual genetic disorder termed Haemophilia B Leyden where patients recover after puberty.[7] The condition results from mutations that disrupt the control region of the clotting factor IX gene.[8][9]
A testosterone-responsive element accounts for post-pubertal recovery.[10] He has also investigated abnormal patterns of globingene expression and his work on mutations associated with the lifelong expression of the fetal haemoglobin gene may help in the treatment of thalassemia and sickle cell anaemia.[11] He is using CRISPR-mediated gene editing to introduce beneficial mutations in cell lines as models for treating genetic diseases.[12][13] Clinical trials by major gene editing companies are now introducing mutations that his lab described.
^Funnell, AP; Crossley, M (January 2014). "Hemophilia B Leyden and once mysterious cis-regulatory mutations". Trends in Genetics. 30 (1): 18–23. doi:10.1016/j.tig.2013.09.007. PMID24138812.
^Crossley, M; Ludwig, M; Stowell, KM; De Vos, P; Olek, K; Brownlee, GG (July 1992). "Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter". Science. 257 (5068): 377–9. Bibcode:1992Sci...257..377C. doi:10.1126/science.1631558. PMID1631558.
^van Vliet, J; Crofts, LA; Quinlan, KG; Czolij, R; Perkins, AC; Crossley, M (April 2006). "Human KLF17 is a new member of the Sp/KLF family of transcription factors". Genomics. 87 (4): 474–82. doi:10.1016/j.ygeno.2005.12.011. PMID16460907.